Guideline on the use of ipecac syrup in the out-of-hospital management of ingested poisons.
ABSTRACT The use of gastric emptying techniques, including ipecac-induced emesis, in the management of poisoned patients has declined significantly in recent years. Historically, poison centers used ipecac syrup in two ways. Ipecac syrup was administered to patients prior to referral to the emergency department in attempts to start the gastric emptying process as early as possible. Additionally, poison centers used ipecac syrup in attempts to keep patients from requiring referral to medical facilities. In these situations, ipecac syrup was administered in the home and poison center staff performed follow-up telephone calls to gauge progress and outcome. Studies to determine the effectiveness of ipecac syrup demonstrate that it induces vomiting in a high percentage of people to whom it is administered and that it decreases the gastrointestinal absorption of ingested substances in a time-dependent fashion. However, the effectiveness of ipecac syrup in affecting patient outcome has not been studied in adequate clinical trials. Its effectiveness in preventing drug absorption has only been documented for a limited number of substances and is substantially reduced if it is given more than 30-90 minutes following ingestion of the toxic material. There are potentially significant contraindications, adverse effects and related problems associated with the use of ipecac syrup. It is the consensus of the panel that the circumstances in which ipecac-induced emesis is the appropriate or desired method of gastric decontamination are rare. The panel concluded that the use of ipecac syrup might have an acceptable benefit-to-risk ratio in rare situations in which: there is no contraindication to the use of ipecac syrup; and there is substantial risk of serious toxicity to the victim; and there is no alternative therapy available or effective to decrease gastrointestinal absorption (e.g., activated charcoal); and there will be a delay of greater than 1 hour before the patient will arrive at an emergency medical facility and ipecac syrup can be administered within 30-90 minutes of the ingestion; and ipecac syrup administration will not adversely affect more definitive treatment that might be provided at a hospital. In such circumstances, the administration of ipecac syrup should occur only in response to a specific recommendation from a poison center, emergency department physician, or other qualified medical personnel. The panel decided not to address the issue of whether ipecac should remain a nonprescription, over-the-counter product. The panel does not support the routine stocking of ipecac in all households with young children but was unable to reach consensus on which households with young children might benefit from stocking ipecac. Instead, the panel concluded that individual practitioners and poison control centers are best able to determine the particular patient population, geographic and other variables that might influence the decision to recommend having ipecac on hand.
Réanimation 10/2006; 15(5). DOI:10.1016/j.reaurg.2006.06.014
Jornal de Pediatria 01/2005; 81(5). DOI:10.1590/S0021-75572005000700012 · 0.94 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Beta-adrenergic blocking agents or β-blockers are prescribed for the treatment of a broad array of common disorders. Their widespread use, coupled with a narrow therapeutic index, contributes to their being a significant cause of poisoning from overdose and the second most common cause of mortality from cardiovascular agents. This article provides an overview of beta-adrenergic system pathophysiology and the properties and pharmacokinetics of β-blockers. Also discussed are the various effects and management of β-blockers in overdose settings.Clinical Pediatric Emergency Medicine 03/2008; 9(1):4-16. DOI:10.1016/j.cpem.2007.12.001